ATNX: way oversold, doubling down here

Doubled down on ATNX at $5.32.

The company is down 50% today based on quarterly results and FDA rejection of their drug. However:

1. the company still has room to fight the decision

2. the company has a portfolio of other products to support its revenue

3. the company has a pipeline of other drugs in development.

Here is the link to my original analysis:


Recent Posts

See All

Sold HZO (+32% profit); Added BDT.CA

Sold HZO, my target was $60 but decided it does not make sense to push it, especially I can use the money for other investments. As mentioned yesterday, bought more BDT (Bird Construction)

Great Q4 results for BDT.CA (adding more tomorrow)

$BDT.CA, a stock I am owning since December 4, 2020, just released super-strong Q4 results. Actually, as expected as per my analysis here: